- Home
- WSBF vs ACIU Comparison
WSBF vs ACIU Comparison
Compare WSBF & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WSBF
- ACIU
- Stock Information
- Founded
- WSBF 1921
- ACIU 2003
- Country
- WSBF United States
- ACIU Switzerland
- Employees
- WSBF N/A
- ACIU N/A
- Industry
- WSBF Savings Institutions
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- WSBF Finance
- ACIU Health Care
- Exchange
- WSBF Nasdaq
- ACIU Nasdaq
- Market Cap
- WSBF 296.4M
- ACIU 332.4M
- IPO Year
- WSBF N/A
- ACIU 2016
- Fundamental
- Price
- WSBF $13.50
- ACIU $2.68
- Analyst Decision
- WSBF
- ACIU Strong Buy
- Analyst Count
- WSBF 0
- ACIU 2
- Target Price
- WSBF N/A
- ACIU $12.00
- AVG Volume (30 Days)
- WSBF 42.3K
- ACIU 132.5K
- Earning Date
- WSBF 01-28-2025
- ACIU 11-05-2024
- Dividend Yield
- WSBF 4.46%
- ACIU N/A
- EPS Growth
- WSBF 40.34
- ACIU N/A
- EPS
- WSBF 0.71
- ACIU N/A
- Revenue
- WSBF $133,232,000.00
- ACIU $48,505,404.00
- Revenue This Year
- WSBF N/A
- ACIU $85.33
- Revenue Next Year
- WSBF N/A
- ACIU $80.69
- P/E Ratio
- WSBF $19.10
- ACIU N/A
- Revenue Growth
- WSBF N/A
- ACIU 4097200.00
- 52 Week Low
- WSBF $10.60
- ACIU $2.25
- 52 Week High
- WSBF $16.86
- ACIU $5.14
- Technical
- Relative Strength Index (RSI)
- WSBF 25.68
- ACIU 27.49
- Support Level
- WSBF $13.30
- ACIU $2.62
- Resistance Level
- WSBF $14.97
- ACIU $3.02
- Average True Range (ATR)
- WSBF 0.39
- ACIU 0.15
- MACD
- WSBF -0.17
- ACIU -0.05
- Stochastic Oscillator
- WSBF 10.47
- ACIU 9.52
About WSBF Waterstone Financial Inc. (MD)
Waterstone Financial Inc is a holding company. Through its subsidiaries, It operates in two segments: Community Banking and Mortgage Banking. The community banking segment provides consumer and business banking products and services to customers, which include various types of loans, deposits, and personal investment services. The Mortgage Banking segment involves residential mortgage loans for the primary purpose of sale in the secondary market. The vast majority of its revenue comes from the community banking segment.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.